Literature DB >> 21816467

A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance.

Qianjun He1, Yu Gao, Lingxia Zhang, Zhiwen Zhang, Fang Gao, Xiufeng Ji, Yaping Li, Jianlin Shi.   

Abstract

A type of pH-responsive nano multi-drug delivery systems (nano-MDDSs) with uniform particle size (100 ± 13 nm) and excellent monodispersity was developed by in situ co-self-assembly among water-insoluble anti-cancer drug (doxorubicin, DOX), surfactant micelles (CTAB) as chemosensitiver and silicon species forming drugs/surfactant micelles-co-loaded mesoporous silica nanoparticles (drugs@micelles@MSNs or DOX@CTAB@MSNs) via a micelles-MSNs self-assembly mechanism. The nano-MDDS DOX@CTAB@MSNs had a highly precise pH-responsive drug release behavior both in vitro and in vivo, and exhibited high drug efficiencies against drug-resistant MCF-7/ADR cells as well as drug-sensitive MCF-7 cells by the MSNs-mediated transmembrane delivery, the sustained drug release and the high anti-cancer and multi-drug resistance (MDR)-overcoming efficiencies. The MDR-overcoming mechanism was proved to be a synergistic cell cycle arrest/apoptosis-inducing effect resulted from the chemosensitization of the surfactant CTAB. These results demonstrated a very promising nano-MDDS for the pH-responsive controlled drug release and the cancer MDR overcoming.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21816467     DOI: 10.1016/j.biomaterials.2011.06.066

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  56 in total

1.  Temperature-activated nucleic acid nanostructures.

Authors:  Ke Zhang; Xiao Zhu; Fei Jia; Evelyn Auyeung; Chad A Mirkin
Journal:  J Am Chem Soc       Date:  2013-09-16       Impact factor: 15.419

2.  Reversal of paclitaxel resistance in human ovarian cancer cells with redox-responsive micelles consisting of α-tocopheryl succinate-based polyphosphoester copolymers.

Authors:  Feng-Qian Chen; Jin-Ming Zhang; Xie-Fan Fang; Hua Yu; Yu-Ling Liu; Hui Li; Yi-Tao Wang; Mei-Wan Chen
Journal:  Acta Pharmacol Sin       Date:  2017-03-06       Impact factor: 6.150

Review 3.  In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles.

Authors:  Altug Ozcelikkale; Hye-Ran Moon; Michael Linnes; Bumsoo Han
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-02-14

Review 4.  Nanobiocatalyst advancements and bioprocessing applications.

Authors:  Mailin Misson; Hu Zhang; Bo Jin
Journal:  J R Soc Interface       Date:  2015-01-06       Impact factor: 4.118

5.  Development of duloxetine hydrochloride loaded mesoporous silica nanoparticles: characterizations and in vitro evaluation.

Authors:  Mani Ganesh; Udhumansha Ubaidulla; Pushparaj Hemalatha; Mei Mei Peng; Hyun Tae Jang
Journal:  AAPS PharmSciTech       Date:  2015-01-22       Impact factor: 3.246

Review 6.  The practicality of mesoporous silica nanoparticles as drug delivery devices and progress toward this goal.

Authors:  Robert Roggers; Shrey Kanvinde; Suthida Boonsith; David Oupický
Journal:  AAPS PharmSciTech       Date:  2014-05-29       Impact factor: 3.246

7.  Co-Delivery of Doxorubicin and Survivin shRNA-Expressing Plasmid Via Microenvironment-Responsive Dendritic Mesoporous Silica Nanoparticles for Synergistic Cancer Therapy.

Authors:  Zhengxiong Li; Linlin Zhang; Cui Tang; Chunhua Yin
Journal:  Pharm Res       Date:  2017-09-25       Impact factor: 4.200

8.  Advanced Functional Nanomaterials for Theranostics.

Authors:  Haoyuan Huang; Jonathan F Lovell
Journal:  Adv Funct Mater       Date:  2016-11-07       Impact factor: 18.808

Review 9.  Serum protein adsorption and excretion pathways of metal nanoparticles.

Authors:  Rodrigo D Vinluan; Jie Zheng
Journal:  Nanomedicine (Lond)       Date:  2015-09-10       Impact factor: 5.307

10.  Materials innovation for co-delivery of diverse therapeutic cargos.

Authors:  Megan E Godsey; Smruthi Suryaprakash; Kam W Leong
Journal:  RSC Adv       Date:  2013-12-21       Impact factor: 3.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.